Opposite Effects of D-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

05/11/2010

in Beckley Science in the Media,BF Scientific Publications,BF Scientific Publications - Intro

ABSTRACT: In healthy individuals, D-9-tetrahydrocannabinol (D-9- THC), the main psychoactive ingredient of the Cannabis sativa plant, can induce psychotic symptoms and anxiety, and can impair memory (D’Souza et al, 2004) and psychomotor control (McDonald et al, 2003; Ramaekers et al, 2006). In patients with schizophrenia, D-9-THC may exacerbate existing psychotic symptoms, anxiety and memory impairments (D’Souza et al, 2005), and D-9-THC is thought to be the ingredient responsible for the increased risk of developing schizophrenia following regular cannabis use (Moore et al, 2007). In contrast, Cannabidiol (CBD), the other major psychoactive constituent of C. sativa, has anxiolytic (Crippa et al, 2004) and possibly antipsychotic properties (Zuardi et al, 2006; Morgan and Curran, 2008; Zuardi, 2008), does not impair memory or other cognitive functions (Fadda et al, 2004; Ilan et al, 2005). Although CBD has been shown to have neuroprotective effects (Hampson et al, 1998; Mechoulam et al, 2002; Lastres-Becker et al, 2005), D-9-THC may have neurotoxic as well as neuroprotective effects (Sarne and Mechoulam, 2005).

FULL DOC: http://archive.beckleyfoundation.org/bib/doc/bf/2009_Sagnik_211516_1.pdf

Neuropsychopharmacology (2009), 1–11

& 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00

www.neuropsychopharmacology.org

Sagnik Bhattacharyya*,1, P Morrison2, P Fusar-Poli1, R Martin-Santos1,3, S Borgwardt1,4, T Winton-Brown1,

C Nosarti5, CM O’ Carroll6, M Seal7, P Allen1, M Mehta8, J Stone1, N Tunstall2, V Giampietro9, S Kapur10,

RM Murray2, AW Zuardi11, JA Crippa11, Z Atakan1 and PK McGuire1

ACKNOWLEDGEMENTS

This work was supported by a grant from the Psychiatry Research Trust, UK. Sagnik Bhattacharyya is supported by a Joint MRC/Priory Clinical research training fellowship from the Medical Research Council, UK. Paul Morrison is supported by the Medical research Council, UK, The Biomedial Research Centre and the Beckley Foundation. Jose A Crippa is recipient of a Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq, Brazil) Productivity fellowship. We thank Glynis Ivin for help with the blinding procedure, storage and dispensing of the drugs. We thank Dr Katya Rubia and Dr Simon Surguladze for allowing us to use the fearful faces and the response inhibition paradigms, respectively.

Leave a Comment